



# ECD Medical Symposium Agenda

Thursday, October 26, 2017 | 7:00 AM to 5:00 PM

<b>7:00 – 8:00</b>	<i>Registration &amp; Continental Breakfast</i>	
<b>8:00 – 8:10</b>	<b>WELCOME ADDRESS</b>	Mark Heaney, MD, PhD <a href="#">Columbia University Medical Center</a>
<b>8:10 – 8:40</b>	<b>GUEST SPEAKER</b>	Neal Rosen, MD, PhD <a href="#">Memorial Sloan Kettering Cancer Center</a>
<b>8:40 – 10:10</b>	<b>BASIC SCIENCE</b>	
<i>6 Oral Presentations (10 min + 5 minute discussion)</i>	1.	Adult Patients with Mixed Histiocytosis: Cases from the NIH Clinical Center. <a href="#">Juvianee Estrada-Veras, MD, National Institutes of Health, Bethesda, MD, USA</a>
	2.	Clinical molecular profiling of archival tumor tissue and cell-free DNA from patients with Erdheim-Chester disease <a href="#">Filip Janku, MD, PhD, MD Anderson Cancer Center, Houston, TX, USA</a>
	3.	Genomic Analysis Identifies Novel Kinase Alterations in the Histiocytic Neoplasms <a href="#">Benjamin H. Durham, M.D., Memorial Sloan Kettering Cancer Center, New York, USA</a>
	4.	BRAF V600E mutation is associated with a cardiac and neurological phenotype but not mortality in Erdheim-Chester disease: results from a single-center 165-patient cohort <a href="#">Julien Haroche, MD, PhD, Pitié-Salpêtrière Hospital, Paris, France</a>
	5.	3-D culture of BRAF- and KRAS- mutated Erdheim-Chester disease tissues: Impact of Kinase Inhibitors <a href="#">Marina Ferrarini, MD, IRCCS San Raffaele Scientific Institute and Università Vita-Salute San Raffaele, Milan, Italy</a>
	6.	BRAF V600E expression in hematopoietic progenitors leads to senescence, myeloid skewing and histiocytosis <a href="#">Riccardo Biavasco, MD, IRCCS San Raffaele Scientific Institute and Università Vita-Salute San Raffaele, Milan, Italy</a>
<b>10:10 – 10:30</b>	<i>Break &amp; Poster Presentations</i>	
<b>10:30 – 11:15</b>	<b>PATHOLOGY</b>	
<i>3 Selected Oral Presentations (10 mins + 5 minute discussion)</i>	7.	Pro-Collagen Type I Expression In Foamy Histiocytes From Erdheim-Chester Disease Biopsies <a href="#">Domenico Corradi, MD, University Hospital of Parma, Parma, Italy</a>
	8.	A cytologic diagnosis of BRAFV600E Erdheim-Chester disease on pericardial fluid. <a href="#">P. Chasseur, MD, Erasme Hospital, Anderlecht, Belgium</a>
	9.	Increased prevalence of myeloid neoplasms in patients with Erdheim-Chester disease <a href="#">Gaurav Goyal, MBBS, Mayo Clinic, Rochester, MN, USA</a>
<b>11:15 – 12:15</b>	<b>TREATMENTS</b>	
<i>4 Selected Oral Presentations (10 mins + 5 minute discussion)</i>	10.	Phase 2 Trial of Single-Agent Cobimetinib for Adults with Histiocytic Disorders: Interim Results <a href="#">Eli L. Diamond, MD, Memorial Sloan Kettering Cancer Center, New York, USA</a>
	11.	Single-agent dabrafenib for BRAFV600E-mutated histiocytosis <a href="#">Ankush Bhatia, MD, Memorial Sloan Kettering Cancer Center, New York, USA</a>
	12.	Efficacy of biologics in the treatment of Erdheim-Chester disease <a href="#">Gaurav Goyal, MBBS, Mayo Clinic, Rochester, MN, USA</a>
	13.	Genomics of Erdheim Chester Disease: Implications for Precision Treatment with Targeted Therapy <a href="#">Aaron M. Goodman, MD, University of California San Diego, La Jolla, CA, USA</a>
<b>12:15 – 12:30</b>	<i>Group Photo of Speakers &amp; Attendees</i>	
<b>12:30 – 1:30</b>	<i>Lunch &amp; Poster Presentations</i>	

<b>1:30 – 2:45</b>	<b>ORGAN INVOLVEMENT &amp; IMAGING</b>	
<i>5 Oral Presentations (10 min + 5 minute discussion)</i>	14. The Masquerader- ECD presenting as PUO Disha Dalela, MBBS, Yale Cancer Biology Institute, New Haven, USA	
	15. Neurologic Involvement in Erdheim-Chester Disease Rahul H. Dave, MD, PhD, National Institutes of Health, Bethesda, MD, USA	
	16. Abdominal and Thoracic Imaging Presentations of 61 Cases of ECD: Association with BRAFV600E Mutation S. Mojdeh Mirmomen and Moozhan Nikpanah, Clinical Center, NIH, Bethesda, MD, USA	
	17. Renal and Ureteral Involvement in ECD: analysis of a single-centre cohort Augusto Vaglio, MD, University Hospital, Parma, Italy	
	18. Comparative Analysis of Tandem PET/CT & PET/MR Studies in the Evaluation of Patients with Inflammatory Myeloid Neoplasms Roei Mazor, MD, Assuta Medical Center, Tel Aviv, Israel	
<b>2.:45 – 3:15</b>	<b>IMPACT:</b> MSKCC targeted tumor sequencing test available for ECD patients	Eli L. Diamond, MD Memorial Sloan Kettering Cancer Center
<b>3:15 – 3:45</b>	<i>Break &amp; Poster Presentations</i>	
<b>3:45 – 4:15</b>	<b>UPDATE CONSENSUS GUIDELINES</b>	Eli L. Diamond, MD Memorial Sloan Kettering Cancer Center
<b>4:15 – 4:45</b>	<b>CLOSING &amp; EVALUATIONS</b>	
	Mark Heaney <a href="#">Columbia University Medical Center</a> Eli L. Diamond <a href="#">Memorial Sloan Kettering Cancer Center</a> Kathleen Brewer <a href="#">ECD Global Alliance</a>	

## Poster Presentations

Title	Author
1. <b>OBSTRUCTIVE UROPATHY AND NEPHROPATHY IN ERDHEIM-CHESTER DISEASE</b>	Kevin J. O'Brien, RN, MS-CRNP <a href="#">National Human Genome Research Institute,</a> <a href="#">The National Institutes of Health, Bethesda, MD, USA</a>
2. <b>ACUTE NON TRAUMATIC CORTICAL SUBARACHNOID HEMORRHAGE REVEALING ERDHEIM-CHESTER DISEASE (ECD)</b>	Thomas Papo, MD <a href="#">Bichat Hospital Paris-Diderot University</a> <a href="#">Paris, France</a>
3. <b>THE SKIN MANIFESTATIONS IN CHINESE PEDIATRIC ERDHEIM-CHESTER DISEASE</b>	Shan Shi-Jun, MD <a href="#">Tianjin Medical University General Hospital, Tianjin, China;</a> <a href="#">Ackerman Academy of Dermatopathology, New York, NY, USA</a>
4. <b>CLINICAL AND RADIOLOGICAL RESPONSES TO ORAL METHOTREXATE IN ERDHEIM-CHESTER DISEASE</b>	Gaurav Goyal, MBBS <a href="#">Mayo Clinic, Rochester, MN, USA</a>
5. <b>ERDHEIM-CHESTER DISEASE GLOBAL ALLIANCE STATISTICS &amp; CENTERS OF CARE</b>	Kathleen Brewer <a href="#">ECD Global Alliance, Louisiana, USA</a>